Stockreport

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Dianthus Therapeutics, Inc.  (DNTH) 
PDF NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advanci [Read more]